Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News

  News Archive

Recreating a T-Cell Receptor Signaling Pathway
Wednesday, April 13, 2016
Successfully re-creating a T-cell receptor signaling pathway independent of the cell itself provides novel insights into how protein signaling works in a complex cellular process.

Investigating Kidney Cancer Therapies
Wednesday, April 13, 2016
Two drugs known to improve survival for patients with metastatic renal cell carcinoma do not reduce the risk of cancer recurrence when administered after surgery.

UCSD Scientists Receive NIH Grant to Combat Antibiotic Resistance
Wednesday, April 13, 2016
Interdisciplinary program will use systems biology approaches to understand how antibiotics work in concert with patient’s immune system.

NanoString, HalioDx Collaborate
Tuesday, April 12, 2016
Company has announced collaboration with HalioDx to jointly develop and commercialize novel gene expression assays in immuno-oncology.

CNS Inflammation: A Pathway and Possible Drug Target
Tuesday, April 12, 2016
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.

Biomarker Discovery Offers Hope For New TB Vaccine
Tuesday, April 12, 2016
A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.

Study Yields the Key to Effective Personalized Medicine
Monday, April 11, 2016
A team of UCLA bioengineers and surgeons has taken a major step toward making personalized medicine a reality.

Galapagos and MorphoSys initiate Phase 1 study
Friday, April 08, 2016
Company has initiated phase 1 study with MorphoSys AG in joint antibody program MOR106.

Regeneron, MedImmune Enter Licensing Agreement
Thursday, April 07, 2016
Companies announce that they have entered into a licensing agreement under which Regeneron will use MedImmune’s pyrrolobenzodiazepine (PBD)-based warhead and linker technology to produce antibodydrug conjugates (ADCs) as potential cancer treatments.

<< 7 8 9 10 11 12 13 >>
Showing Results 91 - 100 of 1878
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!